MOLECULAR IMAGING (MI) ? ABSTRACT The overall goal of the Molecular Imaging (MI) Program at KCI is to develop new imaging technologies through pre-clinical, early clinical and national studies to better understand tumor physiology, aid in the assessment of novel therapeutic approaches and make new imaging methods available to improve routine clinical care. This highly integrated Program includes 24 members from 7 departments and 4 schools at Wayne State University and $3,541,404 in peer reviewed cancer-related funding, of which $772,287 is from the NCI. The MI Program is led by Dr. Juri Gelovani as Program Leader and Dr. Nerissa Viola as a Program Co-Leader. The MI Program is built on close collaborations among the imaging scientists, biomedical engineers, chemists, biologists, clinical oncologists, radiologists, and nuclear medicine physicians. Members with complementary expertise work with colleagues from other KCI Programs to apply their expertise in molecular imaging to answer important biological and clinical questions. Together investigators conduct research using our integrated small animal imaging core facility with optical, 7T MR, microPET/CT, microSPECT/CT, and a recently-installed large animal (clinical) PET/CT scanner, the developing Cyclotron-Radiochemistry Core and other Shared Resources at KCI. Molecular imaging is also being used to complement genetic and epigenetic analyses of tumor specimens. While genetic and epigenetic analyses can investigate thousands of genes simultaneously, imaging allows investigators to study the magnitude and heterogeneity of the gene product expression-activity non-invasively and to obtain such repeated measurements over the course of tumor progression and response to treatment. Furthermore, functional measurements obtained with molecular imaging can assist in determining if a particular pathway is active and if it is important in tumor physiology, something that simple measurements of gene expression or protein level in vitro or in situ may not be able to demonstrate. Bioengineering experts in the MI Program are developing novel instruments and methods for structural, functional, and molecular imaging of cancer, including novel MRI sequences, instruments for hyperpolarization of agents and hpMR spectroscopic imaging, ultrasound tomography and photoacoustic imaging. The ultimate goal of the MI Program is to translate the results of pre- clinical research into the clinic. Several imaging agents, methods, and instruments developed in house? are now progressing to early phase clinical trials. All members of the MI Program actively collaborate with members of the TBM, MT, and PSDR Programs at KCI. Of the 333 manuscripts published between December 2015 and November 2019, 39% and 30% were intra- and inter-programmatic, respectively, and 66% were multi- institutional collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
United States
Zip Code
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008

Showing the most recent 10 out of 826 publications